tetano
Editor, Senior Moderator
ASAIO J
. 2024 Jun 1;70(6):546-552.
doi: 10.1097/MAT.0000000000002120. Epub 2023 Dec 21. COVID-19 Drug Treatments Are Prone to Sequestration in Extracorporeal Membrane Oxygenation Circuits: An Ex Vivo Extracorporeal Membrane Oxygenation Study
Jayesh A Dhanani[SUP] 1 2 [/SUP], Kiran Shekar[SUP] 3 4 [/SUP], Dinesh Parmar[SUP] 3 4 [/SUP], Jeffrey Lipman[SUP] 1 2 5 6 7 [/SUP], Debra Bristow[SUP] 2 [/SUP], Steven C Wallis[SUP] 1 [/SUP], Hayoung Won[SUP] 1 [/SUP], Chandra D Sumi[SUP] 1 [/SUP], Mohd H Abdul-Aziz[SUP] 1 [/SUP], Jason A Roberts[SUP] 1 2 5 6 7 8 [/SUP]
Affiliations
Drug treatments for coronavirus disease 2019 (COVID-19) dramatically improve patient outcomes, and although extracorporeal membrane oxygenation (ECMO) has significant use in these patients, it is unknown whether ECMO affects drug dosing. We used an ex vivo adult ECMO model to measure ECMO circuit effects on concentrations of specific COVID-19 drug treatments. Three identical ECMO circuits used in adult patients were set up. Circuits were primed with fresh human blood (temperature and pH maintained within normal limits). Three polystyrene jars with 75 ml fresh human blood were used as controls. Remdesivir, GS-441524, nafamostat, and tocilizumab were injected in the circuit and control jars at therapeutic concentrations. Samples were taken from circuit and control jars at predefined time points over 6 h and drug concentrations were measured using validated assays. Relative to baseline, mean (± standard deviation [SD]) study drug recoveries in both controls and circuits at 6 h were significantly lower for remdesivir (32.2% [±2.7] and 12.4% [±2.1], p < 0.001), nafamostat (21.4% [±5.0] and 0.0% [±0.0], p = 0.018). Reduced concentrations of COVID-19 drug treatments in ECMO circuits is a clinical concern. Remdesivir and nafamostat may need dose adjustments. Clinical pharmacokinetic studies are suggested to guide optimized COVID-19 drug treatment dosing during ECMO.
. 2024 Jun 1;70(6):546-552.
doi: 10.1097/MAT.0000000000002120. Epub 2023 Dec 21. COVID-19 Drug Treatments Are Prone to Sequestration in Extracorporeal Membrane Oxygenation Circuits: An Ex Vivo Extracorporeal Membrane Oxygenation Study
Jayesh A Dhanani[SUP] 1 2 [/SUP], Kiran Shekar[SUP] 3 4 [/SUP], Dinesh Parmar[SUP] 3 4 [/SUP], Jeffrey Lipman[SUP] 1 2 5 6 7 [/SUP], Debra Bristow[SUP] 2 [/SUP], Steven C Wallis[SUP] 1 [/SUP], Hayoung Won[SUP] 1 [/SUP], Chandra D Sumi[SUP] 1 [/SUP], Mohd H Abdul-Aziz[SUP] 1 [/SUP], Jason A Roberts[SUP] 1 2 5 6 7 8 [/SUP]
Affiliations
- PMID: 38829573
- DOI: 10.1097/MAT.0000000000002120
Drug treatments for coronavirus disease 2019 (COVID-19) dramatically improve patient outcomes, and although extracorporeal membrane oxygenation (ECMO) has significant use in these patients, it is unknown whether ECMO affects drug dosing. We used an ex vivo adult ECMO model to measure ECMO circuit effects on concentrations of specific COVID-19 drug treatments. Three identical ECMO circuits used in adult patients were set up. Circuits were primed with fresh human blood (temperature and pH maintained within normal limits). Three polystyrene jars with 75 ml fresh human blood were used as controls. Remdesivir, GS-441524, nafamostat, and tocilizumab were injected in the circuit and control jars at therapeutic concentrations. Samples were taken from circuit and control jars at predefined time points over 6 h and drug concentrations were measured using validated assays. Relative to baseline, mean (± standard deviation [SD]) study drug recoveries in both controls and circuits at 6 h were significantly lower for remdesivir (32.2% [±2.7] and 12.4% [±2.1], p < 0.001), nafamostat (21.4% [±5.0] and 0.0% [±0.0], p = 0.018). Reduced concentrations of COVID-19 drug treatments in ECMO circuits is a clinical concern. Remdesivir and nafamostat may need dose adjustments. Clinical pharmacokinetic studies are suggested to guide optimized COVID-19 drug treatment dosing during ECMO.